Summit Therapeutics Inc.

SMMT

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase3 readout (AK112 Injection): Apr 2025. Short interest: 21.6% of float.

BiotechnologyCEO: Robert W. DugganIPO: 2015Website ↗

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Catalysts

Phase 3Q2 2025AK112 InjectionNon-Squamous Non-small Cell Lung CancerNCT06396065

Phase 2Mar 24, 2026IvonescimabPleural MesotheliomasNCT06840834

Phase 2May 15, 2026AK112Metastatic Colorectal CancerNCT05382442

Phase 2Jul 1, 2026IvonescimabSalivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland CancerNCT06805617

Phase 2Q3 2026Hyperbaric Oxygen TherapyTBI Traumatic Brain Injury, PTSD - Post Traumatic Stress Disorder, Post Concussive SyndromeNCT07214415

PDUFANov 14, 2026ivonescimabNSCLC

Phase 2Dec 1, 2026IvonescimabStomach Cancer Stage IV, Esophagus Cancer, Stomach CancerNCT07070466

Phase 2Q2 2027IvonescimabEndometrial Cancer, Cervical CancerNCT06925724

Phase 2Jun 17, 2027IvonescimabThymus CarcinomaNCT06980077

Phase 2Aug 1, 2027IvonescimabAdvanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Stage II Head and Neck Cutaneous Squamous Cell CarcinomaNCT07094685

Phase 2Aug 3, 2027IvonescimabBiliary Tract CancerNCT06529718

Phase 2Q3 2027IvonescimabMetastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric AdenocarcinomaNCT06846346

Phase 2Q4 2027Ivonescimab 10 mg/kgExtensive Stage Lung Small Cell CancerNCT07057791

Phase 2Q4 2027IvonescimabTNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast CarcinomaNCT07017673

Phase 2Jan 19, 2028IvonescimabIvonescimab, Clear Cell Renal CarcinomaNCT06940518

Phase 2Jan 31, 2028IvonescimabGlioblastomaNCT06672575

Phase 2Mar 1, 2028IvonescimabLung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell)NCT07405190

Phase 2Q1 2028IvonescimabMetastatic Colorectal CancerNCT07359456

Phase 3Q2 2028Ivonescimab InjectionNon-Small Cell Lung CancerNCT06767514

Phase 3Q2 2028Drug: Ivonescimab InjectionMetastatic Colorectal Cancer (CRC)NCT07228832

Phase 2Jul 1, 2028IvonescimabMetastatic Colorectal CancerNCT06959550

Phase 2Sep 1, 2028IvonescimabCutaneous Squamous Cell CarcinomaNCT06567314

Phase 3Q4 2028Ivonescimab InjectionNon-Small Cell Lung CancerNCT05899608

Phase 2Q2 2029DaraxonrasibAdvanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC)NCT07397338

Phase 3Q1 2030Ivonescimab 10 mg/kgSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)NCT07264075

Phase 2Q1 2031ivonescimabNon Small Cell Lung CancerNCT07234877

Summit Therapeutics Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Recent News & Research

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research